Crockett Sarah
Known title: Chief Marketing OfficerCIK: 0002000092
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Nature's Sunshine Q2 Earnings Reviewed Against Peers. A recent analysis compared Nature's Sunshine's second-quarter results with other personal care companies. This review helps investors understand how the stock performed relative to its sector during that period. The company currently trades with a trailing P/E ratio of 13.3, while analysts maintain an average price target of $30.50.
Transaction History
| CRI | ▼ Sell | Tax Withholding | 2,842 | $114K | 8/8/2026 | View on chart |
| CRI | ▲ Buy | Grant | 7,440 | $0 | 3/2/2026 | View on chart |
| CRI | ▲ Buy | Grant | 11,160 | $0 | 3/2/2026 | View on chart |
| NATR | ▲ Buy | Grant | 12,906 | $0 | 3/11/2024 | View on chart |
| NATR | ▲ Buy | Grant | 13,967 | $0 | 11/2/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Carter's Stock Faces Slip and Lowered Price Target
Recent coverage notes that Carter's shares fell sharply, prompting a price target reduction to $30 by Wells Fargo. Analysts highlighted warning signs in the Russell 2000 and described the stock as potentially undervalued after a 60% decline. The company’s dividend yield of 4.4% and low P/E of 5.9 are cited as attractive income features, while the stock trades near its $37.59 support level.
Carter's Stock Faces Slip and Lowered Price Target. Recent coverage notes that Carter's shares fell sharply, prompting a price target reduction to $30 by Wells Fargo. Analysts highlighted warning signs in the Russell 2000 and described the stock as potentially undervalued after a 60% decline. The company’s dividend yield of 4.4% and low P/E of 5.9 are cited as attractive income features, while the stock trades near its $37.59 support level.